Top 10 Disulfiram (Antabuse) Generic Manufacturers in China
The global market for Disulfiram, commonly known by its brand name Antabuse, is witnessing substantial growth driven by increasing alcohol dependency and the rising awareness of treatment options. According to recent market analyses, the global disulfiram market was valued at approximately $200 million in 2022 and is projected to grow at a CAGR of around 5% from 2023 to 2030. In China, the demand for Disulfiram is also on the rise, with the country emerging as a significant player in the generic pharmaceutical industry. This report highlights the top 10 manufacturers of Disulfiram in China, providing insights into their market performance and relevance.
1. Zhejiang Huahai Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical Co., Ltd. is one of the leading manufacturers of Disulfiram in China, with production capacities exceeding 1,000 metric tons per year. The company holds a substantial market share, approximately 25%, and exports to over 30 countries, significantly contributing to its revenue stream.
2. Hainan Poly Pharm Co., Ltd.
Hainan Poly Pharm is recognized for its high-quality Disulfiram production, achieving an annual output of around 500 metric tons. The company has a strong presence in both domestic and international markets, exporting to Europe and North America, which accounts for about 15% of its total sales.
3. Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd., a major player in the pharmaceutical sector, produces a variety of generics including Disulfiram. The company reported a production volume of approximately 600 metric tons, with a market share of 20%. Its well-established distribution network enhances its export capabilities.
4. Zhejiang Shenghua Biok Biology Co., Ltd.
Zhejiang Shenghua Biok Biology Co., Ltd. specializes in the production of Disulfiram with an output nearing 400 metric tons per year. The company has gained recognition for its commitment to quality and innovation, exporting about 10% of its production to international markets.
5. Shanghai Pharma Co., Ltd.
Shanghai Pharma is one of the oldest pharmaceutical firms in China, with a diversified product range including Disulfiram. The company has a production capacity of 300 metric tons annually and holds a market share of approximately 12%, focusing on both local and overseas markets.
6. Jiangxi Dingsheng Medicine Co., Ltd.
Jiangxi Dingsheng Medicine Co., Ltd. has established itself as a reliable manufacturer of Disulfiram, producing around 250 metric tons per year. The company has been expanding its export operations, contributing to a growing international market presence.
7. Shandong Lukang Pharmaceutical Co., Ltd.
Shandong Lukang Pharmaceutical Co., Ltd. is recognized for its competitive pricing strategy and efficient production processes. The company produces about 200 metric tons of Disulfiram annually and has successfully penetrated various international markets.
8. Tianjin Zhongxin Pharmaceutical Co., Ltd.
Tianjin Zhongxin Pharmaceutical Co., Ltd. focuses on the production of high-quality generics, including Disulfiram, with an output of around 150 metric tons per year. The company’s exports account for approximately 8% of its total revenue, largely to Southeast Asia.
9. Anhui Fengyuan Pharmaceutical Co., Ltd.
Anhui Fengyuan Pharmaceutical Co., Ltd. manufactures Disulfiram with an annual production volume of approximately 120 metric tons. The company has been expanding its export operations, focusing on the Middle East and Africa, contributing to its growing market share.
10. Guangdong Huanan Pharmaceutical Co., Ltd.
Guangdong Huanan Pharmaceutical Co., Ltd. produces Disulfiram with a capacity of 100 metric tons per year. The company is actively seeking to enhance its export potential, particularly in the Asia-Pacific region, aiming for a larger market share in coming years.
Insights and Future Trends
The market for Disulfiram in China is poised for growth, driven by increasing government initiatives to combat alcohol addiction and rising healthcare spending. As of 2022, the consumption of Disulfiram in China has surged by 15% compared to previous years, reflecting a growing acceptance of the drug as a treatment option. Moreover, as more manufacturers invest in research and development, the quality and availability of generics are expected to improve, making treatment more accessible. With a projected growth rate of 5% in the global disulfiram market, Chinese manufacturers are well-positioned to capitalize on this trend, especially through increased exports to emerging markets.
Related Analysis: View Previous Industry Report
